<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23112432</article-id>
      <article-id pub-id-type="pmc">3480803</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-44-649</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.100406</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Olanzapine induced <italic>de-novo</italic> obsessive compulsive disorder in a patient with schizophrenia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kulkarni</surname>
            <given-names>Gajanan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narayanaswamy</surname>
            <given-names>Janardhanan C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Math</surname>
            <given-names>Suresh Bada</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Janardhanan C. Narayanaswamy, E-mail: <email xlink:href="jairamnimhans@gmail.com">jairamnimhans@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2012</year>
      </pub-date>
      <volume>44</volume>
      <issue>5</issue>
      <fpage>649</fpage>
      <lpage>650</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>10</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>5</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>7</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>There are reports of <italic>de novo</italic> development or exacerbation of obsessive-compulsive symptoms in patients with schizophrenia treated with atypical antipsychotics, although this is widely debated. We report one such case where a patient with a primary diagnosis of schizophrenia, treated with olanzapine, developed <italic>de novo</italic> obsessive-compulsive disorder, with convincing evidence for its causality due to the drug.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Obsessive-compulsive disorder</kwd>
        <kwd>olanzapine</kwd>
        <kwd>schizophrenia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-1">
      <title>Introduction</title>
      <p>There are reports of <italic>de novo</italic> production or exacerbation of obsessive-compulsive symptoms (OCS) in patients with schizophrenia treated with atypical antipsychotics.[<xref ref-type="bibr" rid="ref1">1</xref>&#x2013;<xref ref-type="bibr" rid="ref3">3</xref>] This issue has been debated owing to the lack of clarity about the causality of OCS. Since OCS occurs in a proportion of schizophrenia patients without the influence of any drug, it becomes difficult to substantiate the drug-induced causality of OCS. To establish directionality of causation, one needs to demonstrate in a longitudinal manner the occurrence of OCS after initiation of an atypical antipsychotic. We report one such case where a patient with a primary diagnosis of schizophrenia treated with olanzapine, developed <italic>de novo</italic> obsessive-compulsive disorder (OCD), with convincing evidence for its causality due to the drug.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>A 30-year-old married woman presented with symptoms such as suspiciousness, fearfulness, and significant hallucinatory behavior, which impaired her daily functioning, persisting for 3 years. She suspected that the neighbors had been trying to harm her through black magic. She had third person discussing type of auditory hallucinations with derogatory content. The Brief Psychiatric Rating Scale (BPRS) score was 48. A diagnosis of paranoid schizophrenia was made and she was started on olanzapine with 10 mg initially, later increased to 15 mg.</p>
      <p>After 3 weeks of therapy, significant improvement was noted in her symptoms [hallucinations and suspiciousness (BPRS score: 10)]. At this point of time, she started having recurrent sexual thoughts and pathological doubts. She reported significant anxiety associated with these thoughts and felt them to be irrational and uncontrollable. The Yale Brown Obsessive Compulsive Symptoms (YBOCS) score was 18. She fulfilled a diagnosis of OCD with predominant obsessions. Due to the <italic>de novo</italic> emergence of severe obsessions, olanzapine was stopped and aripiprazole was started for psychotic symptoms. After 2 weeks of treatment with aripiprazole, patient's psychotic symptoms worsened within 5 weeks and the BPRS score reached 51. However, the OCD symptoms improved drastically with the YBOCS score reaching 4. Considering the worsening of psychotic symptoms, it was decided to restart olanzapine. While the patient's psychotic symptoms improved dramatically within 2 weeks of treatment, the obsessive symptoms reemerged with the same intensity as earlier. We started the patient on a trial of fluoxetine to 60 mg for OCD. At the end of 8 weeks after starting fluoxetine, OCD remitted and the YBOCS score reached zero. The patient is currently being followed-up for 2 years. There are no psychotic or OCD symptoms and her socio-occupational functioning is normal.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Given the emergence of <italic>de novo</italic> obsessive-compulsive symptoms after starting olanzapine, their resolution after stopping the drug and re-emergence of the symptoms on re-challenge with olanzapine, it was concurred that OCD in this patient was induced by olanzapine. The use of Naranjo <italic>et al</italic>. adverse drug reaction probability scale[<xref ref-type="bibr" rid="ref4">4</xref>] (score = 8) indicated that the adverse effects were probably related to olanzapine itself. Antiserotonergic properties of atypical antipsychotics have been implicated as the underlying mechanism causing obsessions, with an emphasis on their 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor antagonism.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref5">5</xref>] In the case reported here, the obsessive thoughts emerged only after an optimal clinical dosage (15 mg/ day) was reached, suggesting a clear cut relationship between OCD symptom production and drug institution. Compared with the earlier reported cases, the use of a structured and validated scale to ascertain the causal relationship is an advantage in this report. Also this case follows a &#x201C;removal-rechallenge&#x201D; strategy to establish the same unlike the earlier reports. Since it is known that OCD may cooccur in a substantial proportion of schizophrenia patients,[<xref ref-type="bibr" rid="ref6">6</xref>] this aspect must be considered in differentiation of drug-induced OCD symptoms due to the fact the treatment of schizophrenia is primarily with atypical antipsychotics. Close monitoring needs be exercised while starting atypical antipsychotics in schizophrenia since occurrence of OCS as a comorbid condition would affect the prognosis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> No.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lykouras</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alevizos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Michalopoulou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rabavilas</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Obsessive-compulsive symptoms induced by atypical antipsychotics.A review of the reported cases</article-title>
          <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
          <year>2003</year>
          <volume>27</volume>
          <fpage>333</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">12691768</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alevizos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Papageorgiou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Christodoulou</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>Obsessive-compulsive symptoms with olanzapine</article-title>
          <source>Int J Neuropsychopharmacol</source>
          <year>2004</year>
          <volume>7</volume>
          <fpage>375</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">15231024</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schirmbeck</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Esslinger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rausch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Englisch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meyer-Lindenberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zink</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia</article-title>
          <source>Psychol Med</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>2361</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">21466748</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abi-Dargham</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Laruelle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aghajanian</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Charney</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Krystal</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The role of serotonin in the pathophysiology and treatment of schizophrenia</article-title>
          <source>J Neuropsychiatry Clin Neurosci</source>
          <year>1997</year>
          <volume>9</volume>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">9017523</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajkumar</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Kandavel</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Clinical profile of &#x201C;schizo-obsessive&#x201D; disorder: A comparative study</article-title>
          <source>Compr Psychiatry</source>
          <year>2008</year>
          <volume>49</volume>
          <fpage>262</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">18396185</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
